BioCentury | Jul 10, 2020
Product Development

Atox looks towards 3Q20 NDA submission for necrotizing infection candidate following Phase III readout

Following its Phase III readout in necrotizing soft tissue infection, 17-year-old Atox is looking to bring lead product reltecimod to market, with plans to submit an NDA this quarter under the accelerated approval pathway. The...
BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
BioCentury | Dec 8, 2017
Financial News

Atox Bio raises $30M series F

On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners...
BioCentury | Dec 4, 2017
Financial News

Atox Bio raises $30M series F

Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners and Asahi Kasei...
BioCentury | Jun 9, 2017
Clinical News

Reltecimod passes futility analysis in Phase III

Atox Bio Inc. (Ness Ziona, Israel) said an IDMC recommended continuation of the Phase III ACCUTE trial of reltecimod (AB103) to treat necrotizing soft tissue infections (NSTIs) in about 290 patients. The prespecified futility analysis...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

...3564 Antioxidant 1 copper chaperone (ATOX1); copper chaperone for superoxide dismutase (CCS) Breast cancer Cell line studies suggest inhibiting ATOX1...
BioCentury | Nov 2, 2016
Distillery Therapeutics

Infectious disease; inflammation

INDICATION: Sepsis; inflammation Cell culture and mouse studies identified CD86 -derived peptide mimetics that could help treat inflammation association with bacterial sepsis. Chemical synthesis and testing in a bacterial antigen-treated human liver cell line of...
BioCentury | Jun 20, 2016
Company News

Atox Bio, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) exercised an option under a 2014 contract with Atox to develop AB103 to treat necrotizing soft tissue infections. The option brings BARDA’s commitment to $17.4 million; the...
BioCentury | Jan 4, 2016
Clinical News

AB103: Phase III started

Atox began the double-blind, placebo-controlled, U.S. Phase III ACCUTE trial to evaluate single doses of 0.5 mg/kg IV AB103 during or after surgical debridement plus the standard of care (SOC) in about 290 patients. Atox...
BioCentury | Aug 18, 2014
Clinical News

AB103 regulatory update

Atox Bio said the European Commission granted Orphan Drug designation to AB103 to treat necrotizing soft tissue infections. The short peptide that modulates CD28 has completed Phase II testing to treat necrotizing soft tissue infections...
Items per page:
1 - 10 of 22